BridgeMD
New treatment option for Breast Cancer
Official title Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)
ClinicalTrials.gov ID: NCT06085274
What this study is testing
- What it's testing
- This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients who have had chemotherapy as a first treatment using a non-inferiority design. Patients with operable breast cancer treated with chemotherapy and eligible for SLNB will be included in the study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Adults ≥ 18 and ≤ 80
- Stage I-III core biopsy confirmed invasive breast cancer, who have undergone neoadjuvant chemotherapy and are planned to undergo SLNB with dual...
- Eastern Cooperative Oncology Group (ECOG) \< 2
- No ICG/iodine allergy
- Capable of providing informed consent
You likely can't join if
- Significant medical comorbidities (ASA 4)
- Breast cancer stage T4/inflammatory or N2 disease at presentation (SLNB is contra-indicated in this setting)
- Clinical node positive after neoadjuvant therapy (SLNB is contra-indicated in this setting)
- Previous axillary surgery or breast/axillary radiotherapy to ipsilateral breast
- Active pregnancy or breastfeeding
See the full eligibility criteria
- Adults ≥ 18 and ≤ 80
- Stage I-III core biopsy confirmed invasive breast cancer, who have undergone neoadjuvant chemotherapy and are planned to undergo SLNB with dual tracer (blue dye+Tc-99m)
- Eastern Cooperative Oncology Group (ECOG) \< 2
- No ICG/iodine allergy
- Capable of providing informed consent
- English literacy
- Significant medical comorbidities (ASA 4)
- Breast cancer stage T4/inflammatory or N2 disease at presentation (SLNB is contra-indicated in this setting)
- Clinical node positive after neoadjuvant therapy (SLNB is contra-indicated in this setting)
- Previous axillary surgery or breast/axillary radiotherapy to ipsilateral breast
- Active pregnancy or breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.